No abstract

On 31 December 2019 from the Chinese city of Wuhan, Hubei, comes the first case of 'atypical ARDS/interstitial pneumonia'. On 11 February 2020, the WHO officially announced the name of the emergent disease associated with new coronavirus identified as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2): COVID-19 (Coronavirus Disease 2019). 1 On 13 February, 72 000 cases have been officially recorded in China, among which 15 000 were registered in Hubei province only, with 242 deaths in a single day. After that, Chinese republic has ordered drastic containment measures for fighting SARS-CoV-2 virus spreading. 1 On 11 March 2020, the World Health Organization (WHO) stated that the international outbreak of SARS-CoV-2 new coronavirus infection had to be considered a pandemic. 2 To date, 14 April 2020, 213 countries are affected worldwide with 1 812 734 confirmed cases and 113 675 deaths worldwide since the epidemic outbreak. 3 In this scenario, probably the most important strategic goal for dermatologists is to assess what their active involvement in this global pandemic might be. For this reason, our goal is to provide the 'state of the art' on this topic. Our personal experience, and a full extensive review of literature, led us to focus our attention on several topics in the management of dermatological patients during the SARS-CoV-2 pandemic, and four main topics have been identified. They are: (ⅰ) cutaneous manifestations related to COVID-19, (ⅰⅰ) the implications of SARS-CoV-2 infection for use of biological drugs and other immunosuppressive and immunomodulatory therapies in dermatological patients, (ⅰⅰⅰ) occupational skin diseases related to hygienic washing and use of personal protective equipment (PPE) to avoid SARS-CoV-2 infection among patients and clinicians, and (iv) strategic implications in planning dermatological clinical assistance to population during SARS-CoV-2 pandemic. Skin manifestations due to SARS-CoV-2 infection are different and often underestimated, since the general conditions of patients are critical, as in several cases of hospitalized COVID-19. However, the most common symptoms of COVID-19 disease are reported in Table 1. Validated studies encompassing a sufficiently large number of patients to fully describe the most frequent ongoing skin manifestations of COVID-19 are not yet available. However, many Myalgia or arthralgia 164 (14.9) Chills 126 (11.5)

No abstract

No abstract

No abstract